Generated by AI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing investigational therapies for serious neurologically mediated conditions. Its lead program, Haduvio, is an oral extended-release formulation of nalbuphine designed to address chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The company also works on therapies for chronic pruritus and other conditions where opioid receptor modulation may help control symptoms. Trevi Therapeutics serves the specialty respiratory and neurology-adjacent treatment markets, with a business model centered on advancing targeted drug candidates through clinical development and toward potential commercialization. Based in New Haven, Connecticut, Trevi Therapeutics, Inc. focuses on unmet needs in chronic symptom management and operates within the broader biopharmaceutical innovation sector.
Website195 Church Street
New Haven, CT, 06510
United States
The latest articles about TRVI.
Trevi Therapeutics Inc (TRVI) outlines a cash runway into 2030, positive FDA feedback for non-IPF ILD, and a clear path to potential first-in-class status in chronic cough indications.
Summary of Jul 17's posts. Generated by AI.
Summary of Mar 11's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
Investors talking about TRVI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.